Search

for
Search:

Glossary Sunitinib

medication that inhibits enzymes to treat certain cancers

Sunitinib, also known by the brand name Sutent, is a medication used to treat certain types of cancer, including kidney cancer and gastrointestinal stromal tumors. It works by inhibiting multiple protein kinases, which are enzymes involved in the growth and spread of cancer cells.

Related Terms

Sort by

Community Join

30 / 1000+ results

community Consenus on Kx-826/pyrilutamide vs ru58841

11 upvotes 1 week ago

KX-826 is considered effective for hair maintenance, with better safety research than RU58841, but lacks positive anecdotes. RU58841 is seen as potentially stronger, but concerns exist about systemic effects; combining anti-androgens with 5AR inhibitors is suggested for better results.

community Where to buy setipiprant from ?

2 upvotes 1 year ago

The conversation is about hair loss treatments, specifically setipiprant, which the user is considering after experiencing side effects from finasteride and dutasteride. Another user mentions that setipiprant was ineffective in clinical trials.

community Best available SARD right now?

in Treatment 3 upvotes 4 months ago

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

community Kintor long term safety phase 3

in Research/Science 66 upvotes 1 year ago

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

community How promising is kintor pyrilutamide?

in Treatment 13 upvotes 4 years ago

The conversation discusses the potential of kintor pyrilutamide as a promising treatment for hair loss, with ongoing trials in various phases. There is skepticism due to delays in trial results, but the company is actively pursuing further trials.

community when is kintor going to start phase 3 for gt20029?

6 upvotes 2 years ago

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

community GT20029 & KX826 Major Updates from Kintor.

101 upvotes 1 year ago

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

community Thinking about signing up for the setipiprant clinical trials

5 upvotes 9 years ago

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

community Waiting to start treatment until Kintor KX-826 Phase 2 data is published?

17 upvotes 4 years ago

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

community How is the GT20029 different to pyrilutamide as an androgenic antagonist

1 year ago

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

community Kintor money grab, unacceptable

in Product 76 upvotes 1 year ago

Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.

community Anyone immediately lose hope for gt20029 when they realised it’s developed by kintor

7 upvotes 8 months ago

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

community Kintor announcement about pyrilutamide phase 3 results in CHINA

15 upvotes 2 years ago

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

community Kintors 1% Pyrilutamide comes in October/November

in Treatment 21 upvotes 2 years ago

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

community Potentially Positive Pyrilutamide News Coming

6 upvotes 6 months ago

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

community Minoxidil + Tretinoin if you suspect you have low sulfotransferase enzyme activity

in Minoxidil 1 upvotes 1 year ago

Minoxidil may not be effective due to low sulfotransferase activity, and the user considers adding tretinoin to the regimen. They are unsure about the timing and combination with microneedling.

community Pyrilutamide or RU or cb-03-01?

in Minoxidil 2 upvotes 9 months ago

The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.

community Pyrilutamide / KX-826 | Discussion EU

4 upvotes 3 years ago

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

community Kintor starts a new Phase 3 for Pyri... (1+ year)

16 upvotes 3 years ago

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

community Kintor Pharmaceutical’s KX-826 Shows Promising Results in Hair Loss Study

17 upvotes 1 year ago

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

community Pyrilutamide (KX-826) personal consideration

in Research/Science 1 upvotes 1 year ago

Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.

community Pyrilutamide / KX-826 / Koshine — has it been working for you?

10 upvotes 1 year ago

Pyrilutamide/KX-826 is being discussed for its effectiveness in hair regrowth, with some users reporting positive results, especially in early hair loss cases. Users have combined it with treatments like Minoxidil, and some experienced initial shedding before seeing regrowth.

community When will GT20029 phase 3 trial begin?

11 upvotes 1 year ago

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

community Show of hands (US people), who's ordering pyrilutamide?

in Treatment 7 upvotes 2 years ago

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

community Anyone used the 2% pyrilutamide / KX-826 from anagenica or anywhere else?

in Product 2 upvotes 1 year ago

People are discussing hair loss treatments, including pyrilutamide, minoxidil, dutasteride, alfatradiol, and bimatoprost. Users share their experiences and side effects, noting that pyrilutamide is considered more effective and safer than RU58841.

community Article of all potential future cures

25 upvotes 1 year ago

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

community Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China

90 upvotes 3 years ago

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

community Increasing activity of the sult1a1 enzyme via alkalizing agent and tretinoin for better response to topical minoxidil

in Research/Science 4 upvotes 2 years ago

Increasing the sult1a1 enzyme on the scalp may improve response to topical minoxidil. The user suggests using a baking soda solution, DMSO, and tretinoin to enhance enzyme activity and minoxidil effectiveness.

community Kintor 0.9% , save your money friends

in Minoxidil 9 upvotes 5 months ago

Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.

community Pyrilutamide with Alfatradiol and minoxidil (23M)

in Treatment 2 upvotes 9 months ago

The user experienced side effects from a hair loss treatment and is considering using pyrilutamide, alfatradiol, and possibly minoxidil. They are unsure about starting minoxidil immediately or waiting to see the effects of the other treatments.